Henri Romree states that the high margins achieved in Other Accelerators are sustainable in the long term, with continued R&D investments. Olivier Legrain mentions increased R&D investments in Proton Therapy and nuclear medicine, aiming to exceed the 2025 REBIT guidance.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay